These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 34402157)

  • 41. Basal Insulin Degludec and Glycemic Control Compared to Aspart Via Insulin Pump in Type 1 Diabetes (BIGLEAP): A Single-Center, Open-Label, Randomized, Crossover Trial.
    Lane WS; Weinrib SL; Lawrence MJ; Lane BC; Jarrett RT
    Endocr Pract; 2022 Feb; 28(2):165-172. PubMed ID: 34763071
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Continuous Glucose Monitoring in People With Type 1 Diabetes on Multiple-Dose Injection Therapy: The Relationship Between Glycemic Control and Hypoglycemia.
    Oliver N; Gimenez M; Calhoun P; Cohen N; Moscardo V; Hermanns N; Freckmann G; Reddy M; Heinemann L
    Diabetes Care; 2020 Jan; 43(1):53-58. PubMed ID: 31530662
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial.
    Buse JB; Carlson AL; Komatsu M; Mosenzon O; Rose L; Liang B; Buchholtz K; Horio H; Kadowaki T
    Diabetes Obes Metab; 2018 Dec; 20(12):2885-2893. PubMed ID: 30259644
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of fast-acting insulin aspart compared with insulin aspart in combination with insulin degludec in Japanese adults with type 1 diabetes: a subgroup analysis of the randomized onset 8 trial.
    Komatsu M; Ekelund M; Horio H; Kadowaki T
    Endocr J; 2021 Apr; 68(4):429-440. PubMed ID: 33390422
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Quality of Life and Glucose Control After 1 Year of Nationwide Reimbursement of Intermittently Scanned Continuous Glucose Monitoring in Adults Living With Type 1 Diabetes (FUTURE): A Prospective Observational Real-World Cohort Study.
    Charleer S; De Block C; Van Huffel L; Broos B; Fieuws S; Nobels F; Mathieu C; Gillard P
    Diabetes Care; 2020 Feb; 43(2):389-397. PubMed ID: 31843948
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Insulin aspart vs. human insulin in the management of long-term blood glucose control in Type 1 diabetes mellitus: a randomized controlled trial.
    Home PD; Lindholm A; Riis A;
    Diabet Med; 2000 Nov; 17(11):762-70. PubMed ID: 11131100
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1).
    Russell-Jones D; Bode BW; De Block C; Franek E; Heller SR; Mathieu C; Philis-Tsimikas A; Rose L; Woo VC; Østerskov AB; Graungaard T; Bergenstal RM
    Diabetes Care; 2017 Jul; 40(7):943-950. PubMed ID: 28356319
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study.
    Boughton CK; Hartnell S; Thabit H; Poettler T; Herzig D; Wilinska ME; Ashcroft NL; Sibayan J; Cohen N; Calhoun P; Bally L; Mader JK; Evans M; Leelarathna L; Hovorka R
    Diabetes Obes Metab; 2021 Jun; 23(6):1389-1396. PubMed ID: 33606901
    [TBL] [Abstract][Full Text] [Related]  

  • 49. To evaluate the use and clinical effect of intermittently scanned continuous glucose monitoring in adults with type 1 diabetes: Results of a multicentre study.
    Moreno-Fernandez J; Sastre J; Pinés P; Calderon-Vicente D; Gargallo J; Muñoz-Rodriguez JR
    Endocrinol Diabetes Nutr (Engl Ed); 2023 Apr; 70(4):270-276. PubMed ID: 37116972
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and safety of faster aspart in insulin pumps in children and adolescents with type 1 diabetes mellitus: A single-center study with real-world data.
    Stamati A; Sotiriou G; Dimitriadou M; Christoforidis A
    J Diabetes Complications; 2023 Sep; 37(9):108587. PubMed ID: 37597378
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5).
    Klonoff DC; Evans ML; Lane W; Kempe HP; Renard E; DeVries JH; Graungaard T; Hyseni A; Gondolf T; Battelino T
    Diabetes Obes Metab; 2019 Apr; 21(4):961-967. PubMed ID: 30537180
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis.
    Dutta D; Mohindra R; Mahajan K; Sharma M
    Diabetes Metab J; 2023 Jan; 47(1):72-81. PubMed ID: 35746893
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Impact of Switching from Intermittently Scanned to Real-Time Continuous Glucose Monitoring Systems in a Type 1 Diabetes Patient French Cohort: An Observational Study of Clinical Practices.
    Préau Y; Armand M; Galie S; Schaepelynck P; Raccah D
    Diabetes Technol Ther; 2021 Apr; 23(4):259-267. PubMed ID: 33136439
    [No Abstract]   [Full Text] [Related]  

  • 54. Differences for Percentage Times in Glycemic Range Between Continuous Glucose Monitoring and Capillary Blood Glucose Monitoring in Adults with Type 1 Diabetes: Analysis of the REPLACE-BG Dataset.
    Avari P; Uduku C; George D; Herrero P; Reddy M; Oliver N
    Diabetes Technol Ther; 2020 Mar; 22(3):222-227. PubMed ID: 31613142
    [No Abstract]   [Full Text] [Related]  

  • 55. Sustained Impact of Real-time Continuous Glucose Monitoring in Adults With Type 1 Diabetes on Insulin Pump Therapy: Results After the 24-Month RESCUE Study.
    Charleer S; De Block C; Nobels F; Radermecker RP; Lowyck I; Mullens A; Scarnière D; Spincemaille K; Strivay M; Weber E; Taes Y; Vercammen C; Keymeulen B; Mathieu C; Gillard P;
    Diabetes Care; 2020 Dec; 43(12):3016-3023. PubMed ID: 33067260
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A randomized trial of insulin aspart with intensified basal NPH insulin supplementation in people with Type 1 diabetes.
    DeVries JH; Lindholm A; Jacobsen JL; Heine RJ; Home PD;
    Diabet Med; 2003 Apr; 20(4):312-8. PubMed ID: 12675646
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sustained Impact of Intermittently Scanned Continuous Glucose Monitoring on Treatment Satisfaction and Severe Hypoglycemia in Adults with Type 1 Diabetes (FUTURE): An Analysis in People with Normal and Impaired Awareness of Hypoglycemia.
    Charleer S; De Block C; Bolsens N; Van Huffel L; Nobels F; Mathieu C; Gillard P
    Diabetes Technol Ther; 2023 Apr; 25(4):231-241. PubMed ID: 36648249
    [No Abstract]   [Full Text] [Related]  

  • 58. Exploring the inter-subject variability in the relationship between glucose monitoring metrics and glycated hemoglobin for pediatric patients with type 1 diabetes.
    Bosoni P; Calcaterra V; Tibollo V; Malovini A; Zuccotti G; Mameli C; Sacchi L; Bellazzi R; Larizza C
    J Pediatr Endocrinol Metab; 2021 May; 34(5):619-625. PubMed ID: 33823102
    [TBL] [Abstract][Full Text] [Related]  

  • 59. IMpact of flash glucose Monitoring in pEople with type 2 Diabetes Inadequately controlled with non-insulin Antihyperglycaemic ThErapy (IMMEDIATE): A randomized controlled trial.
    Aronson R; Brown RE; Chu L; Bajaj HS; Khandwala H; Abitbol A; Malakieh N; Goldenberg R
    Diabetes Obes Metab; 2023 Apr; 25(4):1024-1031. PubMed ID: 36546594
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of intermittently scanned continuous glucose monitoring in young people with high-risk type 1 diabetes-Extension phase outcomes following a 6-month randomized control trial.
    Rose S; Styles SE; Wiltshire EJ; Stanley J; Galland BC; de Bock MI; Tomlinson PA; Rayns JA; MacKenzie KE; Wheeler BJ
    Diabet Med; 2022 May; 39(5):e14756. PubMed ID: 34862661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.